Independent science reporting on emerging research, policy, and the frontiers of biomedicine and technology.
CGM use by non-diabetic individuals has grown substantially over recent years, driven by wellness industry marketing and biohacking community adoption. What the actual clinical evidence supports for non-diabetic CGM use, what genuine insights emerge, and what remains marketing rather than science.
The gut-brain connection has moved from research curiosity into mainstream health conversation, generating both meaningful scientific advances and substantial overreach. What the actual evidence supports, what remains speculative, and what consumers should understand about the topic.
mRNA technology has moved beyond COVID-19 vaccines into cancer treatment application where the platform's flexibility enables personalized therapies at scale. What the actual clinical results show, which cancers are responding, and what timeline to broader access looks like.
MDMA-assisted therapy approval and psilocybin therapy advances have moved psychedelic medicine from breakthrough excitement into the routine clinical implementation phase. What the actual clinical reality looks like, what the access barriers are, and what remains genuinely uncertain.
Rapamycin and metformin have received substantial attention as potential longevity drugs based on animal research and observational human data. What the actual evidence supports in 2026, what remains speculative, and what the honest risk-benefit picture looks like for off-label longevity use.
Beyond the headlines — long-term weight maintenance data from twelve clinical trials completed in Q2 2026. What the trials actually show about who benefits, who doesn't, and what happens when patients stop.